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journal homepage: www.aidm-onl ine.comEDITORIALLiver cirrhosis as a predisposing risk factor for
esophageal candidiasis: Bystander or culprit?Candida esophagitis is themost common infectious disease of
the esophagus and the most common gastrointestinal oppor-
tunistic disorder among individuals infected with human im-
munodeficiency virus (HIV). Ou et al [1] conducted a study
using a retrospective chart review of non-HIV-infected pa-
tients with esophageal candidiasis and particularly aimed to
elucidate the role of liver cirrhosis in esophageal candidiasis. I
have long thought that retrospectivechart reviewsareusually
poorly done and are subject to all sorts of biases and con-
founding issues. The editorial allowed me to review the
article presented by Ou et al [1] and feel that it shared many
of these problems. Actually,most of theclinical relevant data
of esophageal candidiasis were gathered from HIV-infected
patients. Fungal infections have not been adequately stud-
ied in patients with liver cirrhosis [2]. The main interest had
been focused on acute liver failure and liver transplantation
[3,4]. Thecurrent study is auniqueoneto focusonesophageal
candidiasis in patients with liver cirrhosis thus far and did
identify discussion-worthy issues regarding specific risks in
cirrhotic patients.
In the current study [1], the diagnosis of esophageal
candidiasis was primarily based on endoscopic findings.
Overall, 3017 of 43,217 non-HIV-infected patients had liver
cirrhosis. The incidence of esophageal candidiasis in
cirrhotic patients was higher than that in noncirrhotic pa-
tients (0.8% vs. 0.36%). Liver cirrhosis was identified as an
independent risk factor for esophageal candidiasis (odds
ratio, 1.74; 95% confidence interval, 1.06e2.87). Moreover,
cirrhotic patients tended to be asymptomatic compared
with noncirrhotic patients (45.8% vs. 9%). Antifungal
treatment did not decrease the mortality of patients with
esophageal candidiasis during hospitalization.
Esophageal candidiasis is a common opportunistic infec-
tion in patients when their immunity was compromised.
These included patients with acquired immunodeficiency
such as HIV infection, iatrogenic immunodeficiency such as
organ recipients receiving immunomodulation therapy, can-
cer patients receiving chemotherapy, and other patients who
required long-term steroid therapy. It also occurs in patients
receiving long-term antibiotic and proton pump inhibitorhttp://dx.doi.org/10.1016/j.aidm.2014.06.001
2351-9797/Copyright ª 2014, The Gastroenterological Society of Taiw
Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.therapy, and in patients with major comorbidities such as
diabetes mellitus and renal failure. Esophagogas-
troduodenoscopy (EGD) is a reliable method used to diagnose
esophageal candidiasis by revealing the typical endoscopic
appearance of multiple raised small and thick white plaques
on the esophageal mucosa and histopathology of yeast cells
and pseudohyphae frombiopsy specimens. The prevalence of
esophageal candidiasis in non-HIV-infected patients is
approximately 0.3% [5]. Although it is not a major issue, for
the first time, Ou et al [1] reported that the incidence rate of
esophageal candidiasis in cirrhotic patients was 0.8%, which
was likely overestimated because not all patients with liver
cirrhosis were systemically evaluated by endoscopic exami-
nation and not all of the diagnoses were confirmed by
histopathology.
Patients with liver cirrhosis have compromised immunity
and are predisposed to bacterial infections and selected
fungal infections because of reduced opsonization in blood
and ascites, reduced antibody production, increased immu-
nosuppressive cytokines, disturbances in complement, and
reduced leukocyte function, all of which contribute to the
susceptibility of cirrhotic patients to infections [2,6].
Therefore, it is not surprising to find that liver cirrhosis was
identified as an independent risk factor for esophageal
candidiasis, and the incidence of esophageal candidiasis was
higher in cirrhotic patients with ChildePugh class C.
The common presenting symptoms of esophageal candi-
diasis are nonspecific such as odynophagia, dysphagia, and
retrosternal pain. As observed in the current study, none of
the cases in both groups underwent EGD because of sus-
pected esophageal candidiasis. Moreover, it is often difficult
to recognize the symptoms for esophageal candidiasis
because it usually occurs in concomitance with other dis-
eases. In the current study, almost half of the patients with
liver cirrhosis were asymptomatic. The results should be
interpreted carefully. It is unclear why a large proportion of
patients had no symptom(s) but underwent EGD. I believed
that screening endoscopy had been and should be performed
in many patients with newly diagnosed liver cirrhosis, which
had been highly recommended by international guidelinesan and The Digestive Endoscopy Society of Taiwan. Published by
Editorial 73and consensus [7]. It is likely that screening endoscopy has
led to a higher proportion of asymptomatic patients with
liver cirrhosis in the current study.
Fungal colonization of superficial mucosal sites usually
precedes invasive infection. Systemic antifungal treatment
of esophageal candidiasis was recommended in a recent
clinical practice guidelines proposed by the Infectious Dis-
eases Society of America [8]. Patients with cirrhosis or acute
fulminant liver failure are at increased risk of acquiring
bacterial and selected fungal infections [2e4]. A recent
prospective cohort defined the predisposing factors to
infection-related mortality in hospitalized patients with
cirrhosis [9]. Potentially preventable second bacterial and
fungal infections independently increase mortality in hospi-
talized patients with cirrhosis. Early prevention of these
second infections is suggested. However, whether esopha-
geal candidiasis affected the outcomes of patients with liver
cirrhosis was not reported byOu et al [1]. Instead, they found
no difference in the mortality during hospitalization be-
tween patients with and without antifungal treatment, and
also found that antifungal treatment did not decrease the
mortality in cirrhotic patients with esophageal candidiasis.
The impact of fungal infection on the clinical outcomes
appeared different between prior studies and the current
one. It is likely that the type of fungal infection (chest and
urinary tract vs. esophagus), and disease entity of hosts
(acute vs. chronic, compensation vs. decompensation, and
therapeutic endoscopy vs. screening endoscopy, hospital-
ized vs. outpatient) was unsimilar between these studies.
Therefore, does it matter if esophageal candidiasis occurs in
patientswith liver cirrhosis? The issue needs to be clarified by
further study as suggested by the authors.
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